Tianjin Ringpu Bio-Technology Co.,Ltd. (SHE:300119)
18.23
-0.41 (-2.20%)
Apr 9, 2026, 11:40 AM CST
SHE:300119 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,398 | 3,045 | 2,684 | 2,063 | 1,987 |
Other Revenue | - | 25.33 | 24.98 | 21.44 | 20.23 |
| 3,398 | 3,070 | 2,709 | 2,084 | 2,007 | |
Revenue Growth (YoY) | 10.70% | 13.32% | 29.98% | 3.84% | 0.34% |
Cost of Revenue | 1,996 | 1,820 | 1,527 | 1,075 | 969.26 |
Gross Profit | 1,403 | 1,250 | 1,182 | 1,010 | 1,038 |
Selling, General & Admin | 708.73 | 640.33 | 584.43 | 486.89 | 529.17 |
Research & Development | 253.02 | 196.04 | 172.47 | 132.1 | 116.64 |
Other Operating Expenses | -0.76 | 21.89 | 20.04 | 20.4 | 18.97 |
Operating Expenses | 995.58 | 874.82 | 803.78 | 659.1 | 682.72 |
Operating Income | 407.22 | 375.04 | 378.65 | 350.43 | 355.16 |
Interest Expense | -35.16 | -31.21 | -25.42 | -28.43 | -23.82 |
Interest & Investment Income | 36.71 | 14.11 | 20.81 | 15.25 | 24.27 |
Currency Exchange Gain (Loss) | - | 0.78 | 0.51 | 0.41 | -0.28 |
Other Non Operating Income (Expenses) | -10.88 | -4.63 | -6.12 | 0.43 | -3.21 |
EBT Excluding Unusual Items | 397.89 | 354.08 | 368.42 | 338.1 | 352.12 |
Gain (Loss) on Sale of Investments | 75.83 | -10.71 | 61.26 | 51.38 | 113.8 |
Gain (Loss) on Sale of Assets | 3.82 | -0.02 | 114.09 | -0.01 | 0.1 |
Asset Writedown | -6.85 | -0.14 | -0.47 | -0.11 | -9.1 |
Other Unusual Items | - | 25.07 | 27.89 | 22.16 | 30.88 |
Pretax Income | 470.69 | 368.29 | 571.19 | 413.81 | 487.79 |
Income Tax Expense | 36.22 | 38.46 | 56.18 | 40.04 | 54.2 |
Earnings From Continuing Operations | 434.47 | 329.83 | 515 | 373.77 | 433.59 |
Minority Interest in Earnings | -33.96 | -29.11 | -61.41 | -27.07 | -20.81 |
Net Income | 400.51 | 300.72 | 453.59 | 346.7 | 412.78 |
Net Income to Common | 400.51 | 300.72 | 453.59 | 346.7 | 412.78 |
Net Income Growth | 33.18% | -33.70% | 30.83% | -16.01% | 3.66% |
Shares Outstanding (Basic) | 454 | 460 | 464 | 463 | 402 |
Shares Outstanding (Diluted) | 454 | 460 | 464 | 463 | 402 |
Shares Change (YoY) | -1.29% | -0.69% | 0.11% | 15.06% | 1.61% |
EPS (Basic) | 0.88 | 0.65 | 0.98 | 0.75 | 1.03 |
EPS (Diluted) | 0.88 | 0.65 | 0.98 | 0.75 | 1.03 |
EPS Growth | 34.93% | -33.24% | 30.69% | -27.00% | 2.02% |
Free Cash Flow | 121.43 | 550.21 | 158.47 | 17.05 | 76.75 |
Free Cash Flow Per Share | 0.27 | 1.20 | 0.34 | 0.04 | 0.19 |
Dividend Per Share | - | 0.300 | 0.400 | 0.300 | 0.350 |
Dividend Growth | - | -25.00% | 33.33% | -14.29% | -12.50% |
Gross Margin | 41.28% | 40.71% | 43.65% | 48.44% | 51.71% |
Operating Margin | 11.98% | 12.22% | 13.98% | 16.81% | 17.70% |
Profit Margin | 11.79% | 9.80% | 16.74% | 16.63% | 20.57% |
Free Cash Flow Margin | 3.57% | 17.92% | 5.85% | 0.82% | 3.82% |
EBITDA | 619.37 | 567.43 | 517.4 | 457.89 | 439.13 |
EBITDA Margin | 18.22% | 18.48% | 19.10% | 21.97% | 21.88% |
D&A For EBITDA | 212.15 | 192.39 | 138.76 | 107.45 | 83.97 |
EBIT | 407.22 | 375.04 | 378.65 | 350.43 | 355.16 |
EBIT Margin | 11.98% | 12.22% | 13.98% | 16.81% | 17.70% |
Effective Tax Rate | 7.70% | 10.44% | 9.84% | 9.68% | 11.11% |
Revenue as Reported | 3,398 | 3,070 | 2,709 | 2,084 | 2,007 |
Advertising Expenses | - | 13.04 | 7.44 | 6.64 | 7.72 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.